Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High - Should You Buy?

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reached a new 52-week high at $34.73, closing at $32.83 with a trading volume of 16,549 shares.
• Recent analyst upgrades include a move from "buy" to "strong-buy" by Wall Street Zen, with a consensus rating of "Buy" and an average price target of $41.17.
• The company's latest earnings report showed a profit of $0.23 per share, exceeding estimates, alongside a revenue of $156.80 million for the quarter.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s stock price reached a new 52-week high on Monday . The stock traded as high as $34.73 and last traded at $32.83, with a volume of 16549 shares changing hands. The stock had previously closed at $31.98.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

The stock has a market capitalization of $2.35 billion, a P/E ratio of 803.95 and a beta of 0.14. The firm has a 50-day moving average price of $28.95 and a 200 day moving average price of $24.56.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 18,889 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer directly owned 27,009 shares in the company, valued at $888,326.01. This trade represents a 41.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Paolini sold 29,325 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the transaction, the insider owned 57,403 shares in the company, valued at approximately $1,868,467.65. The trade was a 33.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 500,589 shares of company stock worth $15,262,448 over the last quarter. Company insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in KNSA. JPMorgan Chase & Co. grew its position in shares of Kiniksa Pharmaceuticals International by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock worth $9,451,000 after buying an additional 277,827 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Kiniksa Pharmaceuticals International by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after buying an additional 22,096 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock worth $9,744,000 after buying an additional 9,654 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Kiniksa Pharmaceuticals International by 54.7% in the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock worth $417,000 after buying an additional 7,463 shares during the last quarter. Finally, Martingale Asset Management L P grew its position in shares of Kiniksa Pharmaceuticals International by 1.9% in the 4th quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after buying an additional 900 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.